CYTOSORBENTS ($NASDAQ:CTSO): On November 9 2023, CytoSorbents Corporation announced its earnings results for the third quarter of Fiscal Year 2023 ending September 30 2023. Total revenue for Q3 totaled USD 7.8 million – a 20.0% year-over-year increase – while net income was USD -9.2 million, an improvement compared to the -12.2 million figure of the previous year.
The stock opened at $1.3 and closed at the same value, resulting in a 11.3% plunge from its prior closing price of $1.4. This marked a significant downward trend in the stock, as investors reacted negatively to the news. The dismal performance of the stock on Thursday has analysts predicting that the company’s future outlook is not very optimistic. CYTOSORBENTS CORPORATION has yet to release an official statement regarding their Q3 earnings, leaving investors to speculate what the future of the company holds. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Cytosorbents Corporation. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Cytosorbents Corporation. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Cytosorbents Corporation. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Cytosorbents Corporation are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – Cytosorbents Corporation Intrinsic Value Calculator
At GoodWhale, we recently conducted an analysis of CYTOSORBENTS CORPORATION‘s fundamentals. After carefully evaluating the company’s financials and other performance metrics, we determined that the fair value of CYTOSORBENTS CORPORATION’s stock was around $1.7, which we tracked on our proprietary Valuation Line. However, the current market price of the stock is around $1.3, which implies that it is undervalued by 23.5%. This may be a good opportunity for investors to buy the stock as it is priced below its true value. More…
Star Chart Analysis
The CytoSorb is a blood purification device that removes toxins from the blood. The company’s competitors are PROCEPT BioRobotics Corp, Senzime AB, Natus Medical Inc.
– PROCEPT BioRobotics Corp ($NASDAQ:PRCT)
Procept BioRobotics is a medical device company that develops and commercializes minimally invasive surgical robots. The company’s products include the Corpro robot, which is used for prostatectomy surgery, and the Renovare robot, which is used for kidney surgery. Procept BioRobotics is headquartered in San Carlos, California.
As of 2022, Sensime AB has a market capitalization of 77.38M and a return on equity of -50.55%. The company develops and markets products for the diagnosis and treatment of cardiovascular diseases.
CYTOSORBENTS CORPORATION reported its Q3 FY2023 earnings on November 9 2023, with total revenue up 20.0% year over year and net income down from -12.2 million to -9.2 million. On the same day, the stock price dropped in response to the earnings results. From an investing perspective, this performance is a mixed bag, with strong revenue growth but weak net income. Investors should monitor future developments closely and carefully consider whether or not CYTOSORBENTS CORPORATION is a good fit in their portfolio.